GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...

The UK drugmaker plans to bring the IDRx drug into late stage trials later this year. GSK shares were little changed in early ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

The Brentford, England-based pharmaceutical and biotechnology firm said it will pay USD1.00 billion upfront for IDRx, a developer of precision therapeutics for the treatment of gastrointestinal ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...

London stocks fell in early trade on Monday as bond yields rose again, but oil majors gained in tandem with oil prices.

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...